Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2016, provides an overview of the Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline landscape. Spinal and bulbar muscular atrophy or Kennedy disease is a disorder of specialized nerve cells that control muscle movement. These nerve cells originate in the spinal cord and the part of the brain that is connected to the spinal cord Symptoms include tremors, speech difficulties, muscle weakness, muscle wastage, muscle cramps and spasms and gynaecomastia. Treatment includes balanced diet and medications to reduce muscle cramps and tremors. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders). - The pipeline guide reviews pipeline therapeutics for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) Overview 6 Therapeutics Development 7 Pipeline Products for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Overview 7 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics under Development by Companies 8 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Products under Development by Companies 11 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Companies Involved in Therapeutics Development 12 AndroScience Corp 12 Armgo Pharma Inc 13 Novartis AG 14 Vybion Inc 15 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 ARM-210 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 ASC-J9/ASC-JM.X1 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 ASCJ-9 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 BVS-857 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 INT-41 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Rycal - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Dormant Projects 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Number of Products under Development for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by AndroScience Corp, H2 2016 12 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Armgo Pharma Inc, H2 2016 13 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Novartis AG, H2 2016 14 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Vybion Inc, H2 2016 15 Assessment by Monotherapy Products, H2 2016 16 Number of Products by Stage and Target, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 24 Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) - Dormant Projects, H2 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.